In vivo imaging of HIF-active tumors by an oxygen- dependent degradation protein probe with an interchangeable labeling system

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Kuchimaru, Takahiro ^a   Kadonosono, Tetsuya ^a   Tanaka, Shotaro ^b   Ushiki, Takashi ^c   Hiraoka, Masahiro ^d   Kizaka Kondoh, Shinae ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECOMBINANT PROTEIN; FLUORESCENT DYE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LABELING; CELL SPECIFICITY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PANCREAS CANCER; POINT MUTATION; PROTEIN LOCALIZATION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SCINTISCANNING; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; HELA CELL; HUMAN; MALE; METABOLISM; METHODOLOGY; MOUSE; PANCREAS TUMOR; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANOXIA; FLUORESCENT DYES; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OXYGEN; PANCREATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

EID: 78650824227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015736     Document Type: Article

References (35)

1. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
2. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
3. Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60: 591-597.
4. Kaelin WG (2005) Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
5. Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354.
6. Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
7. Harada H, Kizaka-Kondoh S, Hiraoka M (2006) Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett 580: 5718-5722.
8. Harada H, Hiraoka M, Kizaka-Kondoh S (2002) Antitumor effect of TAToxygen- dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018.
9. Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193.
10. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, et al. (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26: 7508-7516.
11. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67: 4157-4163.
12. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, et al. (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15: 3433-3441.
13. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57: 579-596.
14. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
15. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, et al. (2008) HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 3: 373-382.
16. Kosaka N, Ogawa M, Choyke PL, Karassina N, Corona C, et al. (2009) In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands. Bioconjug Chem 20: 1367-1374.
17. Shah K, Weissleder R (2005) Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2: 215-225.
18. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, et al. (2003) HIF prolylhydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF- 1alpha in normoxia. EMBO J 22: 4082-4090.
19. Chan DA, Sutphin PD, Yen SE, Giaccia AJ (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25: 6415-6426.
20. Arteel GE, Thurman RG, Yates JM, Raleigh JA (1995) Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 72: 889-895.
21. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65: 7259-7266.
22. Depping R, Steinhoff A, Schindler SG, Friedrich B, Fagerlund R, et al. (2008) Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim Biophys Acta 1783: 394-404.
23. Hwang DR, Dence CS, Bonasera TA, Welch MJ (1989) No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Int J Rad Appl Instrum A 40: 117-126.
24. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, et al. (2005) Hypoxiaspecific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46: 106-113.
25. Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, et al. (1999) Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 26: 117-121.
26. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864.
27. Kaelin WG, Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
28. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16.
29. Fels DR, Koumenis C (2005) HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30: 426-429.
30. Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, et al. (2009) Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A 106: 14004-14009.
31. Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, et al. (2009) Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 4: e5077.
32. Harada H, Kizaka-Kondoh S, Itasaka K, Shibuya A, Morinibu K, et al. (2007) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791-796.
33. Contag CH (2007) In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol 2: 277-305.
34. Greer LF, 3rd, Szalay AA (2002) Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 17: 43-74.
35. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465.